poisar

Stocks · News reference

Adlai Nortye Doses First Patient In The Intermittent Weekly Dosing Arm In Its Ongoing Phase 1 Clinical Trial Of AN9025, A Pan-RAS(ON) Inhibitor

Jul 16, 2026, 11:04 AMBenzinga Newsdesk

"Dosing the first U.S. patient with AN9025 on an intermittent weekly schedule is a significant milestone and advances our clinical strategy to evaluate AN9025 with a differentiated approach. We believe based on our

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ANL
Source
benzinga
Observed
Jul 16, 2026, 11:04 AM
Checked
Jul 16, 2026, 11:04 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. Aug 3, 2026, 11:04 AMBenzinga Newsdesk

    Adlai Nortye Submits Clinical Trial Notification To Australia's TGA And Receives Approval From HREC To Commence Phase I Clinical Trial Evaluating AN4035 For Treatment Of CEACAM5-Enriched RAS-Addicted Solid Tumors

    First-in-class pan-RAS(ON) ADC is cleared for clinical developmentDesigned to selectively deliver pan-RAS(ON) inhibition to tumors while minimizing systemic toxicity.IND submissions to U.S. FDA and China NMPA are in

    Read original at benzinga
    ANL